The anti-cytotoxic T-lymphocyte antigen-4 (anti–CTLA-4) antibody ipilimumab is the first
treatment that significantly improved the survival rates of metastatic melanoma patients,
marking a new era in the treatment of melanoma. During its development, a hallmark of
ipilimumab therapy was the extended duration of response, achieved in 20% of patients.
The follow-up of patients included in phase II and phase III trials and in expanded access
programs revealed that the survival rates remained stable after 3 years. These results …